Publications
Cell-Free Systems Used in Real Research
Peer-reviewed research using our cell-free technologies, proteins produced with our systems, and work involving Liberum researchers.
Cell-free expression is most useful when the resulting protein can answer a real biological question. Our systems have been used in applications ranging from functional signalling studies and nanobody diagnostics to distributed biomanufacturing.
Selected Publications
GlycoRNA complexed with heparan sulfate regulates VEGF-A signalling
Nature · 2026
A study investigating the role of glycoRNA and heparan sulfate in VEGF-A signalling.
How our technology was used: The study's methods identify cell-free E. coli protein production by Liberum Biotech for the VEGF-A165-HS wild-type and R/K proteoforms used in functional signalling experiments.
International multisite implementation of distributed cell-free protein biomanufacturing to advance health and research equity
Science Advances · 2026
A ten-site demonstration of distributed cell-free biomanufacturing for research, diagnostics, vaccines and other bioproducts.
How our technology was used: The study used Liberum Juice alongside other cell-free systems and includes Liberum researchers among the authors.
A Rapid and Modular Nanobody Assay for Plug-and-Play Antigen Detection
ACS Synthetic Biology · 2025
RAMONA is a modular nanobody-based antigen detection platform developed for rapid adaptation and point-of-need use.
How our technology was used: Nanobody constructs were expressed directly from linear DNA using Liberum Juice cell-free lysate and a Liberum cell-free optimized expression backbone.
Automated Cell-free Protein Synthesis for Distributed Biomanufacturing
medRxiv · 2025 · Preprint
MANGO is an automated benchtop platform for cell-free protein synthesis and purification at the point of use.
Liberum connection: Liberum researchers are coauthors on the work, which demonstrates automated production of nanobodies, cloning enzymes and diagnostic enzymes.
Independent Coverage
CEPI
2024
Transatlantic scientists to transition traditional vaccine development onto rapid-response platform for faster outbreak control
CEPI highlighted a £2.16 million proof-of-concept program led by CPI to develop the MANGO platform for automated, cell-free production of virus-like particle vaccines.
CEPI identifies Liberum Biotech as a consortium partner alongside CPI, Imperial College London, the University of Leeds, the University of Toronto, the University of Waterloo and Fiocruz.
Nature
2024
Cell-free protein synthesis moves toward on-demand biomanufacturing
Nature highlighted emerging approaches to producing proteins outside living cells and referenced Liberum among companies developing cell-free protein synthesis technologies.
IndieBio
2020
The Future of Drug Manufacturing: Just What The Doctor Ordered
IndieBio featured Liberum's cell-free protein production technology in its discussion of flexible and on-demand biologics manufacturing.
BetaKit
2023
Liberum raises $1.8 million for protein synthesis as a service
BetaKit covered Liberum's seed financing and its work to accelerate recombinant protein production using cell-free technology.
TechCrunch
2020
IndieBio Demo Day: Liberum's protein printer
TechCrunch profiled Liberum during IndieBio's Demo Day, highlighting its approach to rapid recombinant protein production.
Put Cell-Free Expression to Work
Ready-to-use bacterial, yeast and mammalian cell-free systems make it possible to move from DNA to protein without maintaining living expression cultures.